Thymosin Alpha-1
Tα1 · Zadaxin
Thymosin alpha-1 activates TLR2 and TLR9 and supports dendritic-cell activation and maturation. T-cell differentiation shifts toward Th1, with increased production of IL-12, IFN-gamma and IL-2. Natural killer cells are activated, while excessive Th2 and regulatory T-cell activity is inhibited.
Not medical advice. Educational reference only.
- Typical dose
- Subcutaneous: 250 mcg three times weekly or 500 mcg weekly; injectable, route unspecified: 1.6 mg or 3.2 mg twice weekly
- Route
- Subcutaneous injection; injectable, route unspecified
- Storage
- Refrigerate the mixed solution at 2–8 °C; use within 28 days.
What is Thymosin Alpha-1?
Thymosin alpha-1, also known as Tα1 or Zadaxin, contains 28 amino acids and is naturally made in the thymus. It helps regulate immune responses and the maturation of T cells. Approvals in more than 40 countries encompass hepatitis B, adjunctive hepatitis C treatment and immune support for people with cancer. Investigation also includes reducing COVID-19 severity. US prescription compounding for immune support is distinct from FDA approval, and broad international approval does not identify an approval in any particular region.
Mechanism of action
Thymosin alpha-1 activates TLR2 and TLR9 and supports dendritic-cell activation and maturation. T-cell differentiation shifts toward Th1, with increased production of IL-12, IFN-gamma and IL-2. Natural killer cells are activated, while excessive Th2 and regulatory T-cell activity is inhibited.
Targets: TLR2 · TLR9 · Dendritic cells · T lymphocytes
Research indications
Immune Modulation
EffectiveImmune research examines changes in inflammatory responses and the activity of immune cells.
Inflammation Control
EffectivePotential anti-inflammatory effects include lower markers of inflammation locally and throughout the body.
Infection Resistance
ModerateResearch explores possible improvements in the body’s defenses against pathogens.
Research protocols
These are commonly discussed research protocols — not medical advice. Consult a healthcare provider before use.
| Goal | Amount | Frequency | Route |
|---|---|---|---|
| Starting Dose | 250 mcg | 3x weekly | Subcutaneous injection |
| Maintenance Dose | 500 mcg | Weekly | Subcutaneous injection |
Interactions
Medications
CautionConsult your prescriber before combining treatment with any medication.
BPC-157
CompatibleNAD+
CompatibleVitamin D
Compatible
How to reconstitute and inject
Diluent: Use only bacteriostatic water; avoid saline because precipitation can occur.
- Let your refrigerated Thymosin Alpha-1 vial stand for 15–20 minutes so it reaches room temperature before mixing.
- Disinfect the rubber stopper using an alcohol swab. Wait for all of the alcohol to air-dry.
- Measure the calculated bacteriostatic water volume with a sterile syringe. Use BAC water only; saline can lead to precipitation.
- Deliver the water slowly against the vial’s inner wall. Keep the stream from striking the powder directly.
- Mix by gently rotating the vial in circles. Avoid vigorous shaking, which can break down the peptide.
- Wait 2–3 minutes until dissolution is complete. Inspect the liquid for a clear appearance without color.
- Measure your calculated dose in an insulin syringe for administration beneath the skin.
- Choose your abdomen, upper arm or thigh for subcutaneous administration. Change sites between injections to help prevent lipodystrophy.
- Keep the mixed vial at 2–8 °C in the refrigerator. Use the solution within 28 days of preparation.
What to expect
- Week 1–2
- Early effects may emerge during adaptation. Watch for unwanted reactions throughout this period.
- Week 2–4
- The principal effects may begin to appear. Make dose changes only with guidance from your healthcare provider.
- Week 4–8
- The main effects are expected to be more established. Review your progress with a healthcare professional.
- Week 8+
- Assess the results with your provider before deciding whether to continue, cycle treatment or alter the dose.
Side effects and safety
- Bruising, redness or mild pain around the injection area
- Possible allergic reactions; discontinue use if you develop hives or a rash
Frequently asked questions
What is its research focus?
Immune support is the main focus, including T-cell maturation, dendritic-cell function and innate immune signaling. Investigations encompass infectious disease, cancer adjunctive treatment and COVID-19 severity. Broad international use does not by itself establish an FDA approval or a regional approval in the EU, UK or UAE.
Which injectable schedules are discussed?
Numeric research schedules include 250 mcg beneath the skin three times weekly and 500 mcg beneath the skin weekly. Separate discussions name 1.6 mg twice weekly as standard and 3.2 mg twice weekly as intensive, with the injection route unspecified. The approximate injectable half-life is two hours. These are research schedules rather than established human regimens.
What safety information is available?
Individual response, administration route and dose influence adverse effects. Local injection reactions and possible allergy require monitoring. Human studies do not fully characterize every use or formulation. Consult a clinician before use, monitor carefully at the lowest clinician-directed dose and report unusual symptoms.
References
Thymosin alpha 1 in infectious diseases: Perspectives for tomorrow (2017)
Thymosin alpha 1 as adjuvant therapy for melanoma and other cancers (2014)
Immunotherapy for hepatitis B in the direct acting antiviral era: Reevaluating the thymosin α1 efficacy trials in the light of a combination therapy approach. (2018)
Safety and Efficacy of Nucleic Acid Polymers in Monotherapy and Combined with Immunotherapy in Treatment-Naive Bangladeshi Patients with HBeAg+ Chronic Hepatitis B Infection. (2016)
Garaci E — Thymosin α1 immunotherapy review
Thymosin alpha 1: A comprehensive review of the literature (2020)
Thymosin alpha-1 studies on ClinicalTrials.gov (2024)